Related Experiment Video

Updated: Jul 19, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Development of new cancer therapeutic agents targeting mitosis

Mark R Miglarese1, Robert O Carlson

  • 1Array BioPharma, Inc., 3200 Walnut Street, Boulder, CO 80301, USA. mark.miglarese@arraybiopharma.com

Expert Opinion on Investigational Drugs
|October 17, 2006
PubMed

Insights

New antimitotic drugs targeting cellular proliferation show promise in cancer therapy. This review highlights novel agents in clinical trials, aiming for improved efficacy and reduced toxicity compared to traditional microtubule-targeting drugs.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Cancer treatment relies on targeting cellular proliferation.
  • Microtubule-targeting drugs (e.g., taxanes, vinca alkaloids) are effective but have significant side effects.
  • New targets like kinesin spindle protein, Aurora kinases, and Polo-like kinase-1 are emerging for antimitotic therapies.

Purpose of the Study:

  • To review novel antimitotic drugs currently in clinical development.
  • To discuss agents targeting both tubulin and new mitotic targets.
  • To evaluate their potential for improved cancer treatment outcomes.

Main Methods:

  • Review of scientific literature on antimitotic drugs in clinical trials.
  • Focus on drugs targeting microtubules and novel mitotic targets.
  • Analysis of preclinical and early clinical data for efficacy and toxicity.

Main Results:

  • Several novel antimitotic drugs demonstrate promising preclinical activity.
  • New agents are progressing into clinical trials for various cancers.
  • These drugs aim to overcome limitations of existing therapies.

Conclusions:

  • Novel antimitotic drugs offer potential for more effective and safer cancer treatment.
  • Targeting microtubules and new mitotic pathways is a key area of research.
  • Clinical evaluation is crucial to determine the therapeutic value of these agents.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...